RxDoctor Payments Data

Marilyn Robertson, MD

Neurology · San Francisco, CANPI 1679599393

Payments from drug & device makers

$13,716in general payments, 2019–2025

Across 616 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Neurocrine Biosciences, Inc.$792
  • Amneal Pharmaceuticals LLC$786
  • Biogen$728
  • Lilly USA, LLC$705
  • plus $7K from 42 others

What the payments were for

  • Speaking & faculty fees$440%
  • Food & beverage$13,30097%
  • Education$3733%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,716 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$84,996
Medicare patients
80
Services billed
5,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate23$123,957
IngrezzaValbenazine Tosylate12$84,760
BotoxOnabotulinumtoxina50$56,862
RytaryCarbidopa/Levodopa14$33,294
Nurtec OdtRimegepant Sulfate15$22,263
Aimovig AutoinjectorErenumab-Aooe18$13,257
Emgality SyringeGalcanezumab-Gnlm12$8,494
Carbamazepine ErCarbamazepine16$2,909
Primidone20$845
Memantine Hcl40$843
Gabapentin41$770
AmantadineAmantadine Hcl12$757
Carbidopa-LevodopaCarbidopa/Levodopa34$730
Propranolol Hcl ErPropranolol Hcl13$678
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$281$123,95723 claims
Neurocrine Biosciences, Inc.Ingrezza$792$84,76012 claims
AbbVieBotox$2,198$56,86250 claims
Amneal Pharmaceuticals LLCRytary$786$33,29414 claims
PfizerNurtec Odt$257$22,26315 claims
Upsher-smith Laboratories LLCTopiramate$194$20613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →